They don’t have enough cash to fund their developments beyond phase 2. They have no permanent inflow of cash. They will need a lot more cash, time and luck to get their early stage products tested and approved. Phase 3 studies are more expensive and take more time.
There is a cash problem in the long term. They will have to raise more funds.
Additionally how much DPA is in MAT9001? Management does not disclose this. However if you look at the patent, it is mostly EPA with a little DHA and a little DPA.
Research has also found the body can convert EPA to DPA.
Combined I find management’s comments on DPA to be suspect.
Latest Comments
Matinas Biopharma Is Highly Undervalued
The article is one sided and a rehash of managements’ talking points just prior to their presentation. I am pointing out there is more to consider.
Matinas Biopharma Is Highly Undervalued
Management claims that DPA gives their drug an advantage. However it has not been proven to.
Matinas Biopharma Is Highly Undervalued
They don’t have enough cash to fund their developments beyond phase 2. They have no permanent inflow of cash. They will need a lot more cash, time and luck to get their early stage products tested and approved. Phase 3 studies are more expensive and take more time.
There is a cash problem in the long term. They will have to raise more funds.
Matinas Biopharma Is Highly Undervalued
The article failed to mention how one of the LNCs (MAT2203) did not perform as well as the current treatment for VVC in a phase 2 study.
https://clinicaltrials.gov/ct2/show/NCT02971007
Matinas Biopharma Is Highly Undervalued
The claims of the benefits of DPA have not been proven.
www.sciencedirect.com/.../S0952327818301285
Additionally how much DPA is in MAT9001? Management does not disclose this. However if you look at the patent, it is mostly EPA with a little DHA and a little DPA.
Research has also found the body can convert EPA to DPA.
Combined I find management’s comments on DPA to be suspect.